interpreting-hematology-smears

name	interpreting-hematology-smears
description	Structures peripheral blood smear review with morphologic descriptions and differential correlation. Use when reading blood smears, describing cell morphology, or correlating with CBC findings.
tags	["analysis","pathology"]
metadata	{"author":"casemark","practice_areas":["Pathology","Laboratory Medicine"],"document_types":["Interpretation Report"],"skill_modes":["Analysis","Interpretation"]}

Interpreting Hematology Smears

Structures peripheral blood smear review with morphologic descriptions and differential correlation.

Why This Skill Exists

The peripheral blood smear remains an indispensable diagnostic tool that no automated analyzer can fully replace. While modern hematology analyzers provide accurate cell counts, they cannot identify morphologic abnormalities that drive diagnosis: blast cells in acute leukemia, schistocytes in thrombotic microangiopathy, malaria parasites, or hypersegmented neutrophils in megaloblastic anemia. The International Council for Standardization in Haematology (ICSH) and the CLSI H20-A2 guideline establish standards for smear preparation, review criteria, and morphologic grading.

CAP accreditation (Hematology HEM checklist) requires documented criteria for automated smear review triggers, competency in morphologic identification, and quality assurance for manual differentials. CLIA mandates that peripheral blood smear review is performed or supervised by qualified personnel. The pathologist or hematopathologist sign-out on abnormal smears carries the weight of a diagnostic interpretation. Missing schistocytes in a patient with TTP-HUS or failing to identify circulating blasts can result in fatal delays.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. Indication for smear review — Automated flag (blast, left shift, nRBC, large unstained cells), physician request, abnormal CBC, or screening? Default: automated analyzer flag.
2. CBC data — Current CBC with automated differential, reticulocyte count, RBC indices (MCV, MCH, MCHC, RDW)? Default: available.
3. Clinical context — Suspected diagnosis, symptoms (fatigue, bleeding, fever, jaundice), medications, recent surgery/transfusion? Default: not provided; flag [VERIFY].
4. Prior smear reviews — Are there previous smear reports for comparison? Default: none on file.
5. Smear quality — Was the smear prepared from EDTA blood within 2 hours of collection? Default: yes.
6. Stain used — Wright, Wright-Giemsa, or May-Grunwald-Giemsa? Default: Wright-Giemsa.
7. Special stains — Are iron stain, reticulocyte stain, or malarial parasite examination needed? Default: no.

Documents to Request

• Current CBC with automated differential and histogram/scattergram
• Reticulocyte count and reticulocyte hemoglobin content (CHr/Ret-He)
• RBC indices (MCV, MCH, MCHC, RDW)
• Prior CBC and smear reports
• Clinical notes (symptoms, medications, transfusion history)
• Iron studies, B12, folate, LDH, haptoglobin, bilirubin (if hemolysis workup)
• Flow cytometry results (if concurrent)
• Bone marrow biopsy report (if available)

---

Step 1: Smear Quality Assessment

Evaluate the smear in the monolayer (counting) zone before interpreting morphology:

• Monolayer identification: The area where RBCs are evenly distributed, barely touching, and not overlapping. Located approximately 1/3 from the feathered edge.
• Staining quality: Adequate Wright-Giemsa staining shows pink-orange RBCs, purple WBC nuclei, and pink-blue WBC cytoplasm. Over-staining or under-staining can mimic hypochromia or obscure granulation.
• EDTA artifact assessment: > 2-hour-old EDTA specimens may show neutrophil hypersegmentation, platelet swelling, and crenated RBCs. Flag if specimen age > 4 hours.
• Platelet satellitism: EDTA-dependent phenomenon; if noted, recommend recollection in citrate for accurate platelet count.

---

Step 2: Red Blood Cell Morphology

Systematically evaluate RBC morphology using standardized grading:

RBC Morphology Grading (ICSH/CAP Recommendations)

Abnormality	Grading Scale	Clinical Significance
Microcytes	Slight/Moderate/Marked (1+/2+/3+)	Iron deficiency, thalassemia, chronic disease, sideroblastic anemia
Macrocytes	1+/2+/3+	B12/folate deficiency, MDS, liver disease, reticulocytosis, drugs (hydroxyurea, AZT)
Hypochromia	1+/2+/3+	Iron deficiency, thalassemia, chronic disease
Polychromasia	1+/2+/3+	Reticulocytosis (hemolysis, bleeding, recovery)
Spherocytes	1+/2+/3+	Hereditary spherocytosis, autoimmune hemolytic anemia, burns
Schistocytes	1+/2+/3+ (> 1% = significant)	TTP/HUS, DIC, HELLP, mechanical heart valve, March hemoglobinuria
Target cells	1+/2+/3+	Thalassemia, hemoglobin C, liver disease, post-splenectomy
Sickle cells	Present/absent	Sickle cell disease (HbSS, HbSC)
Teardrop cells (dacrocytes)	1+/2+/3+	Myelofibrosis, myelophthisis, thalassemia major
Rouleaux	1+/2+/3+	Multiple myeloma, Waldenstrom, chronic inflammation
Agglutination	Present/absent	Cold agglutinin disease, ABO incompatibility
Nucleated RBCs (nRBCs)	Per 100 WBCs	Severe anemia, bone marrow infiltration, post-splenectomy, neonatal
Howell-Jolly bodies	Present/absent	Functional asplenia, post-splenectomy, megaloblastic anemia
Basophilic stippling	Present/absent	Lead poisoning, thalassemia, MDS, pyrimidine 5' nucleotidase deficiency
Pappenheimer bodies	Present/absent	Sideroblastic anemia, post-splenectomy (confirm with iron stain)

Critical Schistocyte Assessment

Per ICSH 2012 consensus: Schistocytes are fragments with two or more pointed extremities (helmet cells, triangle cells, crescent cells). Microspherocytes and keratocytes may coexist. A count of > 1% schistocytes is significant and should prompt evaluation for TMA (TTP, HUS, DIC).

---

Step 3: White Blood Cell Differential and Morphology

Perform a 200-cell manual differential (or 100-cell if WBC < 1.0 x 10^9/L):

WBC Differential Interpretation

Cell Type	Normal %	Increased (Shifted)	Key Morphologic Abnormalities
Neutrophils	40-70%	Bacterial infection, inflammation, stress	Toxic granulation, Dohle bodies, vacuolation (toxic changes), hypersegmentation (>= 5 lobes = megaloblastic)
Lymphocytes	20-40%	Viral infection, CLL, lymphoma	Atypical lymphocytes (reactive/viral), smudge cells (CLL), large granular lymphocytes
Monocytes	2-8%	CMML, recovery from neutropenia, chronic infection	Promonocytes with folded nuclei and fine granules
Eosinophils	1-4%	Allergy, parasites, drug reaction, eosinophilic disorders	Degranulation, hypogranulation
Basophils	0-1%	CML, basophilic leukemia, allergy	Confirm with toluidine blue if needed
Blasts	0%	Acute leukemia, MDS, blast crisis CML	Auer rods (pathognomonic for AML), high N:C ratio, fine chromatin, nucleoli

Critical WBC Findings — Immediate Action Required

Finding	Immediate Action
Blasts > 5% in peripheral blood	Critical value notification; recommend bone marrow biopsy and flow cytometry
Auer rods identified	Report as "blasts with Auer rods, consistent with acute myeloid leukemia"
Atypical cells suspicious for circulating lymphoma	Recommend flow cytometry
Leukoerythroblastic reaction (nRBCs + left shift)	Evaluate for bone marrow infiltration (myelophthisis)
Neutrophil hypersegmentation (>= 5% with 5+ lobes)	Evaluate for B12/folate deficiency

---

Step 4: Platelet Estimation and Morphology

• Platelet estimate: Count platelets in 10 oil-immersion fields in the monolayer; average x 20,000 = estimated platelet count. Compare to automated count. Discrepancy > 30% warrants investigation (clumping, satellitism, giant platelets).
• Platelet morphology: Normal size (2-4 um), large platelets (> 4 um), giant platelets (approaching RBC size), platelet clumps (pseudothrombocytopenia).
• Causes of large/giant platelets: ITP, MYH9-related disorders, Bernard-Soulier syndrome, myeloproliferative neoplasms.
• Platelet clumping: If present, recommend recollection in citrate tube for accurate count. EDTA-dependent pseudothrombocytopenia affects ~0.1% of patients.

---

Step 5: Report Construction and Clinical Correlation

Assemble the smear interpretation report:

1. CBC correlation: State agreement or discrepancy between automated and smear-based estimates.
2. RBC morphology: Grade each abnormality using standardized scale. Comment on predominant finding.
3. WBC differential: Report 200-cell manual differential with absolute counts. Flag critical findings.
4. Platelet estimate: Concordant or discordant with automated count. Comment on morphology.
5. Impression/Comment: Integrate morphologic findings with clinical context. Provide differential diagnosis.
6. Recommendations: Suggest additional testing (flow cytometry, bone marrow, hemolysis labs, iron studies).

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Was the smear reviewed in the correct monolayer zone with adequate staining quality?
2. Are all RBC morphologic abnormalities graded using standardized terminology (1+/2+/3+)?
3. Was a 200-cell manual differential performed for the WBC assessment?
4. Were critical findings (blasts, schistocytes > 1%, Auer rods) communicated as critical values?
5. Is the smear interpretation correlated with the automated CBC and clinical context?

---

Quality Audit

• Smear quality assessed (monolayer zone, stain quality, specimen age)
• RBC morphology systematically evaluated and graded per ICSH/CAP standards
• Schistocyte percentage quantified when fragments are present
• 200-cell manual differential performed (or 100-cell if WBC < 1.0 x 10^9/L)
• Blast cells identified and reported with morphologic description
• Auer rods specifically sought and documented when blasts are present
• Neutrophil toxic changes graded (granulation, Dohle bodies, vacuolation)
• Platelet estimate performed and compared to automated count
• Platelet clumping assessed and citrate recollection recommended if present
• nRBC count reported per 100 WBCs with corrected WBC count
• Smear findings correlated with automated CBC indices
• Critical findings reported via critical value notification pathway
• Parasites specifically evaluated when clinically indicated (travel, fever)

---

Guidelines

• Always review the smear in the monolayer zone; evaluating morphology in thick or thin areas produces systematic errors in cell sizing and staining assessment
• Grade all RBC morphologic abnormalities using a standardized scale (1+/2+/3+); avoid vague terms like "few" or "some"
• Quantify schistocytes as a percentage when present; > 1% is clinically significant and should trigger evaluation for thrombotic microangiopathy (TTP/HUS, DIC)
• Report all blasts seen on peripheral smear as a critical value requiring immediate clinician notification, regardless of the percentage
• Auer rods are pathognomonic for acute myeloid leukemia; their identification on a peripheral smear should be reported urgently even in the absence of a formal blast count
• Correct the automated WBC count when nucleated RBCs are present: corrected WBC = reported WBC x [100 / (100 + nRBCs per 100 WBCs)]
• For EDTA-dependent platelet clumping (pseudothrombocytopenia), recommend recollection in a citrate tube and correct the count by multiplying by 1.1 (for 3.2% citrate dilution)
• Correlate smear findings with clinical context in every report; morphology without clinical integration provides limited diagnostic value